- Home
- CCIA vs HUMAW Comparison
CCIA vs HUMAW Comparison
Compare CCIA & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- HUMAW
- Stock Information
- Founded
- CCIA N/A
- HUMAW 2004
- Country
- CCIA
- HUMAW United States
- Employees
- CCIA N/A
- HUMAW 220
- Industry
- CCIA
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- HUMAW Health Care
- Exchange
- CCIA Nasdaq
- HUMAW Nasdaq
- Market Cap
- CCIA N/A
- HUMAW N/A
- IPO Year
- CCIA 2023
- HUMAW N/A
- Fundamental
- Price
- CCIA $25.12
- HUMAW $0.31
- Analyst Decision
- CCIA
- HUMAW
- Analyst Count
- CCIA 0
- HUMAW 0
- Target Price
- CCIA N/A
- HUMAW N/A
- AVG Volume (30 Days)
- CCIA N/A
- HUMAW 14.2K
- Earning Date
- CCIA N/A
- HUMAW 03-21-2025
- Dividend Yield
- CCIA N/A
- HUMAW N/A
- EPS Growth
- CCIA N/A
- HUMAW N/A
- EPS
- CCIA N/A
- HUMAW N/A
- Revenue
- CCIA N/A
- HUMAW N/A
- Revenue This Year
- CCIA N/A
- HUMAW N/A
- Revenue Next Year
- CCIA N/A
- HUMAW N/A
- P/E Ratio
- CCIA N/A
- HUMAW N/A
- Revenue Growth
- CCIA N/A
- HUMAW N/A
- 52 Week Low
- CCIA N/A
- HUMAW $1.18
- 52 Week High
- CCIA N/A
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- CCIA 36.06
- HUMAW 55.81
- Support Level
- CCIA $25.10
- HUMAW $0.26
- Resistance Level
- CCIA $25.39
- HUMAW $0.40
- Average True Range (ATR)
- CCIA 0.11
- HUMAW 0.05
- MACD
- CCIA -0.02
- HUMAW 0.01
- Stochastic Oscillator
- CCIA 7.21
- HUMAW 55.00
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.